USFDA approves Encorafenib plus Cetuximab and Chemo in BRAF V600E-positive mCRC
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Accelerated approval is based on 61% overall response rate compared to 40% in control arm in the
Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
First and only PARP inhibitor to improve overall survival in early breast cancer
Partnership to supercharge LVMH Recherche with Integrated Biosciences’ innovative AI and synthetic biology platform for targeting skin aging
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Despite NTC014, due to its simplified therapeutic regimen, has been administered at a lower posology than the antibiotic comparator
The product will be marketed by Dr. Reddy's
This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions
Subscribe To Our Newsletter & Stay Updated